List of most commonly encountered drugs currently controlled under the misuse of drugs legislation
Updated 8 August 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/controlled-drugs-list--2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation
The following is a list of the most commonly encountered drugs currently controlled under the misuse of drugs legislation showing their respective classifications under both the Misuse of Drugs Act 1971 (MDA) and the Misuse of Drugs Regulations 2001 (MDR).
Although it is extensive, the list is not exhaustive and, in the event of a substance not being listed below, reference should also be made to the published Act and Regulations at legislation.gov.uk, specifically Parts I, II, III and IV of Schedule 2 to the Misuse of Drugs Act 1971 and in Schedules 1 to 5 to the Misuse of Drugs Regulations 2001.
Please note that on opening the content of any item of legislation that has outstanding changes and effects waiting to be applied to it, the outstanding effects are listed at the top of the provision.
This list is not exhaustive. All salts (e.g. calcium, HCl, sodium and sulphate), stereoisomers, esters, ethers, preparations and products are also controlled where stated in the legislation.
| Drug | Class | Schedule |
|---|---|---|
| MDA | MDR | |
| Acetorphine | A | 2 |
| Acetyldihydrocodeine | B[footnote 1] | 2/5[footnote 2] |
| Adinazolam | C | 1 |
| Alfentanil | A | 2 |
| Allobarbital (allobarbitone) | B | 3 |
| Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine (MDAL) | A | 1 |
| Allylprodine | A | 2 |
| Alphacetylmethadol | A | 2 |
| Alphameprodine | A | 2 |
| Alphamethadol | A | 2 |
| α-Methylfentanyl | A | 1 |
| Alphaprodine | A | 2 |
| Alphenal (5-Allyl-5-Phenylbarbituric acid) | B | 3 |
| Alprazolam | C | 4 Pt1 |
| Amineptine | C | 2 |
| Aminorex | C | 4 Pt1 |
| Amphetamine | B[footnote 1] | 2 |
| Amobarbital (Amylobarbitone) | B | 3 |
| Androst-4-ene-3,17-diol (4-Androstenediol) | C | 4 Pt2 |
| Anhydroecgonine | A | 2 |
| Anileridine | A | 2 |
| Aprobarbital (Aprobarbitone) | B | 3 |
| Atamestane | C | 4 Pt2 |
| Barbital (Barbitone) | B | 3 |
| Barbituric acid, (any 5,5-disubstituted) | B | 3 |
| Benzethidine | A | 2 |
| Benzoylecgonine | A | 2 |
| Benzphetamine | C | 3 |
| Benzyl(α-Methyl-3,4-methylenedioxyphenethyl)amine | A | 1 |
| Benzylmorphine (3-Benzylmorphine) | A | 2 |
| Betacetylmethadol | A | 2 |
| Betameprodine | A | 2 |
| Betamethadol | A | 2 |
| β-Methoxy-3,4-methylenedioxyphenethylamine | A | 1 |
| Betaprodine | A | 2 |
| Bezitramide | A | 2 |
| Bolandiol | C | 4 Pt2 |
| Bolasterone | C | 4 Pt2 |
| Bolazine | C | 4 Pt2 |
| Boldenone | C | 4 Pt2 |
| Boldione | C | 4 Pt2 |
| Bolenol | C | 4 Pt2 |
| Bolmantalate | C | 4 Pt2 |
| Bromazepam | C | 4 Pt1 |
| Bromazolam | C | 1 |
| Bromophenethylamine | A | 1 |
| Brotizolam | C | 4 Pt1 |
| Bufotenine (5-Methoxydimethyltryptamine) | A | 1 |
| Buprenorphine | C | 3 |
| Butabarbital (Secbutobarbital) | B | 3 |
| Butalbital | B | 3 |
| Butallylonal | B | 3 |
| Butethal (Butobarbital/Butobarbitone) | B | 3 |
| Calusterone | C | 4 Pt2 |
| Camazepam | C | 4 Pt1 |
| Cannabinol | B | 1 |
| Cannabinol derivatives (except dronabinol or its stereoisomers) | B | 1 |
| Cannabis | B | 1[footnote 11] |
| cannabis resin | B | 1 |
| cannabis oil | B | 1 |
| “Sativex” | B | 4 Pt1[footnote 10] |
| Carfentanyl (Carfentanil) | A | 2 |
| Cathine ((+)-norpseudoephedrine) | C | 3 |
| Cathinone | C | 1 |
| Cathinone derivatives | B | 1 |
| CBPMs | B | 2 |
| Chlordiazepoxide | C | 4 Pt1 |
| Chloromethamphetamine | B | 1 |
| Chloroamphetamine | A | 1 |
| Chlorphentermine | C | 3 |
| Chlorophenethylamine | A | 1 |
| Chorionic gonadotrophin (HCG) | C | 4 Pt2 |
| Clenbuterol | C | 4 Pt2 |
| Clobazam | C | 4 Pt1 |
| Clonazepam | C | 4 Pt1 |
| Clonazolam | C | 1 |
| Clonitazene | A | 2 |
| Clorazepic acid (Clorazepate) | C | 4 Pt1 |
| Clostebol | C | 4 Pt2 |
| Clotiazepam | C | 4 Pt1 |
| Cloxazolam | C | 4 Pt1 |
| Coca leaf | A | 1 |
| Cocaethylene (ethylbenzoylecgonine) | A | 2 |
| Cocaine | A | 2 |
| Codeine | B[footnote 1] | 2/5[footnote 2] |
| Cyclobarbital (Cyclobarbitone) | B | 3 |
| Cyclopentobarbital (Cyclopentobarbitone) | B | 3 |
| Cyclopropylmethyl(α-Methyl-3,4-methylenedioxyphenethyl)amine | A | 1 |
| Danazol | C | 4 Pt2 |
| Delorazepam | C | 4 Pt1 |
| Deschloroetizolam | C | 1 |
| Desomorphine | A | 2 |
| Desoxymethyltestosterone | C | 4 Pt2 |
| Desoxypipradrol (2-Diphenylmethyl-piperidine, 2-DPMP) | B | 1 |
| Dextromoramide | A | 2 |
| Dextropropoxyphene | C | 2/5[footnote 3] |
| Diamorphine (Diacetylmorphine) | A | 2 |
| Diampromide | A | 2 |
| Diazepam | C | 4 Pt1 |
| Diclazepam | C | 1 |
| Diethylpropion | C | 3 |
| Diethylthiambutene | A | 2 |
| Difenoxin | A | 2/5[footnote 4] |
| Dihydrocodeine | B[footnote 1] | 2/5[footnote 2] |
| Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine | A | 1 |
| α,α-Dimethyl-3,4-methylenedioxyphenethylamine | A | 1 |
| α,α-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine | A | 1 |
| Dihydrocodeinone-O-carboxymethyloxime | A | 2 |
| Dihydroetorphine | A | 2 |
| Dihydromorphine | A | 2 |
| Dimenoxadole | A | 2 |
| Dimepheptanol | A | 2 |
| Dimethylthiambutene | A | 2 |
| Dioxaphetyl butyrate | A | 2 |
| Diphenoxylate | A | 2/5[footnote 5] |
| Diphenylprolinol (Diphenyl-2-pyrrolidinyl-methanol, D2PM) | B | 1 |
| Dipipanone | A | 2 |
| Dronabinol | B | 2 |
| Drotebanol (3,4-Dimethoxy-17-methylmorphinan- 6, 14-diol) | A | 2 |
| Drostanolone | C | 4 Pt2 |
| Ecgonine and any derivative of ecgognine which is convertible to ecgonine or cocaine | A | 2 |
| Enestebol | C | 4 Pt2 |
| Epidyolex | B | 5 |
| Epitiostanol | C | 4 Pt2 |
| Estazolam | C | 4 Pt1 |
| Ethchlorvynol | C | 3 |
| Ethinamate | C | 3 |
| Ethyl loflazepate | C | 4 Pt1 |
| Ethylmethylthiambutene | A | 2 |
| Ethylmorphine (3-Ethylmorphine) | B[footnote 1] | 2[footnote 2] |
| Ethylnaphthidate | B | 1 |
| Ethyloestrenol | C | 4 Pt2 |
| Ethylphenidate | B | 1 |
| Eticyclidine | A | 1 |
| Etizolam | C | 1 |
| Etonitazene | A | 2 |
| Etorphine | A | 2 |
| Etoxeridine | A | 2 |
| Etryptamine | A | 1 |
| Fencamfamin | C | 4 Pt1 |
| Fenethylline | C | 2 |
| Fenproporex | C | 4 Pt1 |
| Fentanyl | A | 2 |
| Flualprazolam | C | 1 |
| Flubromazepam | C | 1 |
| Flubromazolam | C | 1 |
| Fludiazepam | C | 4 Pt1 |
| Flunitrazepam | C | 3 |
| Flunitrazolam | C | 1 |
| Fluorophenethylamine | A | 1 |
| Fluoxymesterone | C | 4 Pt2 |
| Flurazepam | C | 4 Pt1 |
| Fonazepam | C | 1 |
| Formebolone | C | 4 Pt2 |
| Fungus (of any kind) which contains psilocin or an ester of psilocin | A | 1 |
| Furazabol | C | 4Pt2 |
| Furethidine | A | 2 |
| Gabapentin (1-(aminomethyl) cyclohexaneacetic acid) | C | 3 |
| Gamma-butyrolactone (GBL) (for human ingestion) | B | n/a[footnote 9] |
| Gamma-hydroxybutyrate (GHB - 4-Hydroxy-n-butyric acid) | B | 2 |
| Gestrinone | C | 4 Pt2 |
| Glutethimide | B | 2 |
| Halazepam | C | 4 Pt1 |
| Haloxazolam | C | 4 Pt1 |
| Heptobarbital (Heptobarbitone) | B | 3 |
| Hexethal | B | 3 |
| Homoveratrylamine (3,4-Dimethoxyphenethylamine) | A | 1 |
| Hydroxybenzoylecgonine | A | 2 |
| Hydroxycocaine | A | 2 |
| Hydrocodone (dihydrocodeinone) | A | 2 |
| Hydromorphinol (14-Hydroxydihydromorphine) | A | 2 |
| Hydromorphone | A | 2 |
| Hydroxypethidine | A | 2 |
| Isomethadone | A | 2 |
| Isopropylphenidate | B | 1 |
| Ketamine | B | 2 |
| Ketazolam | C | 4 Pt1 |
| Ketobemidone | A | 2 |
| Khat | C | 1 |
| Lefetamine | B | 2 |
| Levomethorphan | A | 2 |
| Levomoramide | A | 2 |
| Levophenacylmorphan | A | 2 |
| Levorphanol/Dextrorphan | A | 2 |
| Lisdexamphetamine | B | 2 |
| Lofentanil | A | 2 |
| Loprazolam | C | 4 Pt1 |
| Lorazepam | C | 4 Pt1 |
| Lormetazepam | C | 4 Pt1 |
| Lysergamide | A | 1 |
| Lysergic acid diethylamide (LSD) | A | 1 |
| Lysergic Acid N-(Methylopropyl) Amide | A | 1 |
| Lysergide (& other N-alkyl derivatives of lysergamide) | A | 1 |
| Mazindol | C | 3 |
| Mebolazine | C | 4 Pt2 |
| Meclonazepam | C | 1 |
| Mecloqualone | B | 2 |
| Medazepam | C | 4 Pt1 |
| Mefenorex | C | 4 Pt1 |
| Mephentermine | C | 3 |
| Mepitiostane | C | 4 Pt2 |
| Meprobamate | C | 3 |
| Mesabolone | C | 4 Pt2 |
| Mescaline | A | 1 |
| Mesocarb | C | 4 Pt1 |
| Mestanolone | C | 4 Pt2 |
| Metazocine | A | 2 |
| Mesterolone | C | 4 Pt2 |
| Methadone | A | 2 |
| Methadyl acetate | A | 2 |
| Methylamphetamine | A | 2 |
| Methylmorphenate | B | 1 |
| Methylnaphthidate | B | 1 |
| α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine | A | 1 |
| α-Methylphenethylhydroxylamine | B | 2 |
| Methandienone | C | 4 Pt2 |
| Methandriol | C | 4 Pt2 |
| Methaqualone | B | 2 |
| Methcathinone (Ephedrone) | B | 1 |
| Methenolone | C | 4 Pt2 |
| Methoxyphenethylamine | A | 1 |
| Methyldesorphine | A | 2 |
| Methyldihydromorphine (6-methyldihydromorphine) | A | 2 |
| Methylecgonine | A | 2 |
| Methylenedioxyamphetamine (MDA) | A | 1 |
| Methylenedioxyethylamphetamine (MDEA) | A | 1 |
| Methylenedioxypyrovalerone (MDPV) | B | 1 |
| Methylphenidate | B[footnote 1] | 2 |
| Methylphenobarbital (Methylphenobarbitone) | B | 3 |
| Methyltestosterone | C | 4 Pt2 |
| Methyprylone | C | 3 |
| Metizolam | C | 1 |
| Metopon | A | 2 |
| Metribolone | C | 4 Pt2 |
| Mibolerone | C | 4 Pt2 |
| Midazolam | C | 3 |
| Morpheridine | A | 2 |
| Morphine | A | 2/5[footnote 6] |
| 3-Monoacetylmorphine (3-MAM) | A | 2 |
| 6-Monoacetylmorphine (6-MAM) | A | 2 |
| Morphine-3-B-D-Glucoride-N-Oxide | A | 2 |
| Morphine-3-B-D-Glucuronide | A | 2 |
| Morphine-6-B-D-glucuronide-N-oxide | A | 2 |
| Morphine methobromide (& morphine N-oxide & other pentavalent nitrogen morphine derivatives) | A | 2 |
| Myrophine | A | 2 |
| N-Benzyl-ethylphenidate | B | 1 |
| N-Benzylpethidine | A | 1 |
| N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine | A | 1 |
| N-(2,5-Dimethoxy-4-propylthiophenthyl)hydroxylamine | A | 1 |
| N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine | A | 1 |
| N,N-Diethyltryptamine (DET) | A | 1 |
| N,N-Dimethyltryptamine (DMT) | A | 1 |
| N-Ethylamphetamine | C | 4 Pt1 |
| N-Ethyl-1(3-methoxyphenyl)cyclohexylamine (3-MeO-PCE) | B | 1 |
| N-Hydroxy-tenamphetamine (MDOH) | A | 1 |
| N-Methylhomoveratrylamine | A | 1 |
| N-Methyl Lysergic Acid Diethylamide | A | 1 |
| N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) | A | 1 |
| N-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine | A | 1 |
| N-Methyltryptamine | A | 1 |
| Nabilone | B | 2 |
| Nandrolone | C | 4 Pt2 |
| Napthylpyrovalerone (naphyrone) | B | 1 |
| Nealbarbitone | B | 3 |
| N-ethyl-nor-ketamine | B | 1 |
| Nicocodine | B[footnote 1] | 2/5[footnote 2] |
| Nicodicodine (6-nicotinoyldihydrocodeine) | B[footnote 1] | 2/5[footnote 2] |
| Nicomorphine (3,6-dinicotinoyl-morphine) | A | 2 |
| Nifoxipam | C | 1 |
| Nimetazepam | C | 4 Pt1 |
| Nitrazepam | C | 4 Pt1 |
| Nitrazolam | C | 1 |
| Non-human chorionic gonadotrophin | C | 4 Pt2 |
| Noracymethadol | A | 2 |
| Norboletone | C | 4 Pt2 |
| Norclostebol | C | 4 Pt2 |
| Norcocaine | A | 2 |
| Norcodeine | B[footnote 1] | 2/5[footnote 2] |
| Nordazepam | C | 4 Pt1 |
| Norethandrolone | C | 4 Pt2 |
| Norfludiazepam | C | 1 |
| Norlevorphanol | A | 2 |
| Normethadone | A | 2 |
| Normorphine | A | 2 |
| Norpethidine (4-Phenylpiperidine-4-carboxylic acid ethyl ester) | A | 1 |
| Norpipanone | A | 2 |
| O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine | A | 1 |
| Opium: | ||
| Raw | A | 1 |
| Prepared or medicinal | A | 2[footnote 6][footnote 7] |
| Oripavine | C | 2 |
| Ovandrotone | C | 4 Pt2 |
| Oxabolone | C | 4 Pt2 |
| Oxandrolone | C | 4 Pt2 |
| Oxazepam | C | 4 Pt1 |
| Oxazolam | C | 4 Pt1 |
| Oxycodone | A | 2 |
| Oxymesterone | C | 4 Pt2 |
| Oxymetholone | C | 4 Pt2 |
| Oxymorphone | A | 2 |
| Pemoline | C | 4 Pt1 |
| Pentazocine | B | 3 |
| Pentobarbital (Pentobarbitone) | B | 3 |
| Pethidine (Meperidine) | A | 2 |
| Phenadoxone | A | 2 |
| Phenampromide | A | 2 |
| Phenazepam (7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) | C | 3 |
| Phenazocine | A | 2 |
| Phencyclidine (PCP) | A | 2 |
| Phendimetrazine | C | 3 |
| Phenmetrazine | B[footnote 1] | 2 |
| Phenobarbital (Phenobarbitone) | B | 3 |
| Phenomorphan | A | 2 |
| Phenoperidine | A | 2 |
| Phentermine | C | 3 |
| Pholcodine (Morpholinylethylmorphine) | B[footnote 1] | 2/5[footnote 2] |
| Piminodine | A | 2 |
| Pinazepam | C | 4 Pt1 |
| Pipradrol | C | 3 |
| Piritramide | A | 2 |
| Poppy straw (and concentrate) | A | n/a |
| Prasterone (Dehydroepiandrosterone DHEA) | C | 4 Pt2 |
| Prazepam | C | 4 Pt1 |
| Pregabalin ((S)–3–(aminomethyl)-5-methylhexanoic acid) | C | 3 |
| Probarbital (Probarbitone) | B | 3 |
| Proheptazine | A | 2 |
| Propallylonal | B | 3 |
| Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester) | A | 2 |
| Propetandrol | C | 4 Pt2 |
| Propiram | B | 2/5[footnote 8] |
| Propylbenzoylecgonine | A | 2 |
| Propylphenidate | B | 1 |
| Prostanozol | C | 4 Pt2 |
| Proxibarbital (Proxibarbitone) | B | 3 |
| Psilocin | A | 1 |
| Pyrazolam | C | 1 |
| Pyrovalerone | C | 4 Pt1 |
| Quinalbarbital (Quinalbarbitone/Secobarbital) | B | 2 |
| Quinbolone | C | 4 Pt2 |
| Racemethorphan | A | 2 |
| Racemoramide | A | 2 |
| Racemorphan | A | 2 |
| Remifentanil | A | 2 |
| Rolicyclidine | A | 1 |
| Roxibolone | C | 4 Pt2 |
| Secbutobarbital (Secbutobarbitone) | B | 3 |
| Silandrone | C | 4 Pt2 |
| Somatotropin | C | 4 Pt2 |
| Somatrem | C | 4 Pt2 |
| Somatropin | C | 4 Pt2 |
| Stanolone | C | 4 Pt2 |
| Stanozolol | C | 4 Pt2 |
| Stenbolone | C | 4 Pt2 |
| Sufentanil | A | 2 |
| Talbutal | B | 3 |
| Tapentadol | A | 2 |
| Temazepam | C | 3 |
| Tenocyclidine | A | 1 |
| Testosterone | C | 4 Pt2 |
| Tetrahydrocannabinol (Delta-THC) | B | 1 |
| Tetrahydrogestrinone | C | 4 Pt2 |
| Tetrazepam | C | 4 Pt1 |
| Thebacon (acetyldihydrocodeinone) | A | 2 |
| Thebaine | A | 2 |
| Thiomesterone | C | 4 Pt2 |
| Tilidine | A | 2 |
| Tramadol | C | 3 |
| Trenbolone | C | 4 Pt2 |
| Triazolam | C | 4 Pt1 |
| Trimeperidine | A | 2 |
| U-47,700 | A | 1 |
| Vinbarbital (Vinbarbitone) | B | 3 |
| Vinylbital (Vinylbitone) | B | 3 |
| Zaleplon | C | 4 Pt1 |
| Zeranol | C | 4 Pt2 |
| Zilpaterol | C | 4 Pt2 |
| Zipeprol | B | 2 |
| Zolpidem | C | 4 Pt1 |
| Zopiclone | C | 4 Pt1 |
| 1-Androstenediol | C | 4 Pt2 |
| 1-Androstenedione | C | 4 Pt2 |
| 1-Benzylpiperazine (BZP) | C | 1 |
| 1-(Benzofuran-5-yl)-propan-2-amine (5-APB) | B | 1 |
| 1-(Benzofuran-6-yl)-propan-2-amine (6-APB) | B | 1 |
| 1-Benzyl-4-methylpiperazine (BZMP) | C | 1 |
| 1,4-Butanediol (1,4-BD) (for human ingestion) | B | n/a[footnote 9] |
| 1-(3-Chlorophenyl)-4-(3-chloropropyl)piperazine (CPCPP) | C | 4 Pt1 |
| 1-(3-Chlorophenyl)piperazine (mCPP) | C | 4 Pt1 |
| 1-(4-Chlorophenyl)piperazine (pCPP) | C | 1 |
| 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45) | A | 1 |
| 1,4-Dibenzylpiperazine (DBZP) | C | 1 |
| 1-(2,3-Dihydro-1-benzofuran-5-yl)-propan-2-amine (5-APDB) | B | 1 |
| 1-(2,3-Dihydro-1-benzofuran-6-yl)-propan-2-amine (6-APDB) | B | 1 |
| 1-(4-Fluorophenyl)piperazine (pFPP) | C | 1 |
| 1-(5-Fluoropentyl)-3-(4-methyl-naphthoyl)indole (MAM-2201) | B | 1 |
| 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694) | B | 1 |
| 1-(5-Fluoropentyl)-3-(naphthalen-1-oyl)indole (AM-2201) | B | 1 |
| 1-Methyl-4-phenylpiperidine-4-carboxylic acid | A | 2 |
| 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine | A | 1 |
| 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine | A | 1 |
| 1-(3-Methylphenyl)piperazine (mMPP) | C | 1 |
| 1-(4-Methoxyphenyl)piperazine (pMeOPP) | C | 1 |
| 1-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine (3-MeO-PCP) | B | 1 |
| 1-[1-(4-Methoxyphenyl)cyclohexyl]-piperidine (4-MeO-PCP) | B | 1 |
| 1-(4- Methylphenyl)piperazine (pMPP) | C | 1 |
| 1-Pentyl-3-(2-iodobenzoyl)indole (AM-679) | B | 1 |
| 1-Pentyl-3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole (UR-144) | B | 1 |
| 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) | C | 1 |
| 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol | A | 1 |
| 2-Amino-1-(3,4-dimethoxyphenyl)ethanol | A | 1 |
| 2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl] ethanamine (25B-NBOMe) | A | 1 |
| 2-Chloro-6-fluorophenethylamine | A | 1 |
| 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) | A | 1 |
| 2-(1,4-Dimethoxy-2-naphthyl)ethylamine | A | 1 |
| 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine | A | 1 |
| 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine | A | 1 |
| 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine | A | 1 |
| 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine | A | 1 |
| 2,5-Dimethoxy-4-(N)-propylthiophenethylamine (2C-T-7) | A | 1 |
| 2-(3,4-Dimethoxyphenyl)ethylamine (Homoveratrylamine) | A | 1 |
| 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine | A | 1 |
| 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine | A | 1 |
| 2,4-Dichlorophenethylamine | A | 1 |
| 2,4-Dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone (LSZ) | A | 1 |
| 2,5-Dimethoxy-4-Bromoamphetamine | A | 1 |
| 2,5-Dimethoxy-4-Iodoamphetamine | A | 1 |
| 2,5-Dimethoxy-4-Methylamphetamine | A | 1 |
| 2,5-Dimethoxy--4-dimethylphenethylamine | A | 1 |
| 2,5-Dimethoxy-4-iodoamphetamine | A | 1 |
| 2-(2,5-Dimethoxy-4-methylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25D-NBOMe) | A | 1 |
| 2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol (O-Desmethyltramadol) | B | 1 |
| 2,6-Dichlorophenethylamine | A | 1 |
| 2-Diphenylmethylpyrrolidine | B | 1 |
| 2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexanone (Methoxetamine) | B | 1 |
| 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) | A | 1 |
| 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine | A | 1 |
| 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine | A | 1 |
| 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[β]furan-6-yl)-1-methylethylamine | A | 1 |
| 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[β]furan-6-yl)-1-methylethylamine | A | 1 |
| 2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol | A | 1 |
| 2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine | A | 1 |
| 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone | B | 1 |
| 2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid | A | 2 |
| 2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (butylone) | B | 1 |
| 2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone) | B | 1 |
| β,2,5-Trimethoxy-4-methylphenethylamine | A | 1 |
| 3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921) | A | 1 |
| 3-Fluoromethcathinone (3-FMC) | B | 1 |
| 3-Hydroxyphenazepam | C | 1 |
| 3-Hydroxy-4-methoxyphenethylamine | A | 1 |
| 3-Hydroxy-5α-androstan-17-one | C | 4 Pt2 |
| 3-Methoxy-4-ethoxy-α-methylphenethylamine | A | 1 |
| 3-Methoxy-4-Hydroxyamphetamine | A | 1 |
| 3-Methoxy-4-Hydroxymethamphetamine | A | 1 |
| 3-Methoxy-4-Hydroxyphenethylamine | A | 1 |
| 3-Methylfentanyl | A | 1 |
| 3,4-Dichloroethylphenidate | B | 1 |
| 3,4-Dichloromethylphenidate | B | 1 |
| 3,4-Dichlorophenethylamine | A | 1 |
| 3,4-Dimethoxyamphetamine | A | 1 |
| 3,4-Dimethoxyphenethylamine | A | 1 |
| 3,4-Methylenedioxy-N,N-dimethylamphetamine | A | 1 |
| (3,4-Methylenedioxymethamphetamine, MDMA) | A | 1 |
| β,3,4,5-Tetramethoxyphenethylamine | A | 1 |
| 4-Androstene-3, 17-dione | C | 4 Pt2 |
| 4-Bromo-2,5-dimethoxy-α-methylphenethylamine | A | 1 |
| 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) | A | 1 |
| 4-Bromo-β,2,5-trimethoxyphenethylamine | A | 1 |
| 4-Bromo-2,5-dimethoxy--methylphenethylamine | A | 1 |
| 4’-Chlorodiazepam | C | 1 |
| 4-Chloro-2,5-dimethoxyphenethylamine (2C-C) | A | 1 |
| 4-Chloromethandienone | C | 4 Pt2 |
| 4-Cyano-1-methyl-4-phenylpiperidine | A | 2 |
| 4-Cyano-2-dimethylamino-4,4-diphenylbutane | A | 2 |
| 4-Fluoroethylphenidate | B | 1 |
| 4-Fluoromethylphenidate | B | 1 |
| 4-Hydroxy-3-methoxyphenethylamine (HMMA) | A | 1 |
| 4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine | A | 1 |
| 4-Methyl-aminorex | A | 1 |
| 4-Methylmethcathinone (Mephedrone) | B | 1 |
| 4-Methylmethylphenidate | B | 1 |
| 4-Methylthioamphetamine (α-Methyl-4-methylthio)phenethylamine | A | 1 |
| 4-Methoxymethcathinone (bk-PMMA/methedrone) | B | 1 |
| 4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR) | A | 1 |
| 5-(2-Aminopropyl)indole (5-IT) | B | 1 |
| 5-Androstenedione | C | 4 Pt2 |
| 5α-Androstane-3,17-diol | C | 4 Pt2 |
| 5-Androstene-3,17-diol | C | 4 Pt2 |
| 5-Methoxydimethyltryptamine (5-MeO-DMT) | A | 1 |
| (6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52) | A | 1 |
| 6-(2-Aminopropyl)indole (6-IT) | B | 1 |
| (6aR,9R) R,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD) | A | 1 |
| (6aR,9R) R,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD) | A | 1 |
| (6aR,9R) R,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD) | A | 1 |
| 6-β-Hydroxytestosterone | C | 4 Pt2 |
| 14-Hydroxymorphine | A | 2 |
| 19-Norandrostenedione | C | 4 Pt2 |
| 19-Norandrosterone | C | 4 Pt2 |
| 19-Noretiocholanolone | C | 4 Pt2 |
| 19-Nor-5-Androstene-13,17-diol | C | 4 Pt2 |
| 19-Nor-4-Androstene-3,17-dione | C | 4 Pt2 |
-
Falls within paragraph 6 of Part I of Schedule 2 of the MDA 1971 (ie Class A) if in a preparation designed for administration by injection. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11
-
Falls within Schedule 5 if any preparation of one or more of the substances to which this note applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5 percent (calculated as base) in undivided preparations. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
-
On 1 November 2018, Cannabis-based products for medicinal use in humans (CBPMs) were introduced under Schedule 2 to the Misuse of Drugs Regulations 2001. Only products meeting the definition of a CBPM in regulation 2(1) of the Misuse of Drugs Regulations 2001 were rescheduled. Products not meeting this definition (other than cannabis-based medicines that have received marketing authorisation and have been separately scheduled) have remained in Schedule 1 which means they cannot be accessed except under a Home Office licence. ↩
-
“Sativex” is the first cannabis-based medicine (oral spray) recognised in the UK to have medicinal properties. Following marketing authorisation, the ACMD recommended that “Sativex” should be placed in Part I of Schedule 4 to the 2001 Regulations. ↩
-
Falls within Schedule 5 if in a preparation designed for oral administration, containing not more than 135 mg of dextropropoxyphene (calculated as base) per dosage unit or with a concentration of not more than 2.5 percent (calculated as base) in undivided preparations. ↩
-
Falls within Schedule 5 if in any preparation of difenoxin containing, per dosage unit, not more than 0.5 mg of difenoxin and a quantity of atropine sulphate equivalent to at least 5 percent of the dose of difenoxin. ↩
-
Falls within Schedule 5 if in any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 mg of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1 percent of the dose of diphenoxylate. ↩
-
GBL and 1,4-BD are not inserted into any Schedule to the 2001 Regulations. Instead, because of their legitimate industrial uses, regulation 4B of the 2001 Regulations makes it lawful to import, export, produce, supply, offer to supply or possess these substances except where a person does so knowing or believing that they will be used for the purpose of human ingestion. ↩ ↩2
-
Falls within Schedule 5 if in a preparation of medicinal opium or morphine containing (in either case) not more than 0.2 percent of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine, cannot be recovered by readily applicable means or in a yield which would constitute a risk to health. ↩ ↩2
-
Falls within Schedule 5 if in any powder of ipecacuanha and opium comprising: 10 percent opium, in powder, 10 percent ipecacuanha root, in powder, well mixed with 80 percent of any other powdered ingredient containing no controlled drug. ↩
-
Falls within Schedule 5 if in a preparation containing, per dosage unit, not more than 100 mg of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose. ↩